Search results
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
Zacks via Yahoo Finance· 3 months agoCorvus Pharmaceuticals, Inc. CRVS announced that the FDA granted the Orphan Drug Designation to its...
Where Will Recursion Pharmaceuticals Be in 5 Years?
Motley Fool via Yahoo Finance· 3 weeks agoAs a biotech that's planning to go big on artificial intelligence (AI) for drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is a decidedly...
Can Axsome Hold Out Till Depression Drug Becomes a Blockbuster?
Motley Fool· 1 year agoAxsome Therapeutics' (NASDAQ: AXSM) psychiatric drug Auvelity could reach blockbuster status by the...
Biotech Stock Finds Favor Among Mutual Fund Managers
Investor's Business Daily· 1 year agoBioMarin Pharmaceutical executed a hyper-bullish breakaway gap in late November as it broke out of a double-bottom base with a buy point of 92.86. The...
PTC Stock Has Gained 41% This Week Alone, And It's Still Sprinting
Investor's Business Daily· 2 years agoShares of PTC stock on Thursday continued a seven-day run —including a 41% sprint this week — on...
Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment
TipRanks via Yahoo Finance· 3 months agoAmong the range of central nervous system (CNS) disorders afflicting patients in the U.S. each year,...
Amgen dives deeper into rare disease drugs with $27.8 billion Horizon deal
Reuters via Yahoo Finance· 1 year ago(Reuters) -Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8...
3 Biotech Stocks Outperforming a Bear Market
InvestorPlace via Yahoo Finance· 2 years ago2022 is likely to go down as one of the most challenging years for investors since 2008. Year-to-date, the S&P 500 is down more than 20%, while there is...
5 Healthcare Stocks to Buy for 2024
InvestorPlace via Yahoo Finance· 1 month agoWhat has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ:SMCI), that would be a great answer....
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
Zacks via Yahoo Finance· 8 months agoMoleculin (MBRX) completes enrollment in the phase II portion of the development program for its...
